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Adherence to medication among individuals with chronic obstructive pulmonary disease (COPD) is suboptimal and
has negative impacts on survival and health care costs. No systematic review has examined the effectiveness of
interventions designed to improve medication adherence. Electronic databases Medline and Cochrane were
searched using a combination of MeSH and keywords. Eligible studies were interventions with a primary or
secondary aim to improve medication adherence among individuals with COPD published in English. Included
studies were assessed for methodological quality using the Effective Practice and Organisation of Care (EPOC)
criteria. Of the 1,186 papers identified, seven studies met inclusion criteria. Methodological quality of the studies
was variable. Five studies identified effective interventions. Strategies included: brief counselling; monitoring and
feedback about inhaler use through electronic medication delivery devices; and multi-component interventions
consisting of self-management and care co-ordination delivered by pharmacists and primary care teams. Further
research is needed to establish the most effective and cost effective interventions. Special attention should be
given to increasing patient sample size and using a common measure of adherence to overcome methodological
limitations. Interventions that involve caregivers and target the healthcare provider as well as the patient should be
further explored.
Keywords: Medication adherence, Medication compliance, Chronic obstructive pulmonary disease, Systematic
reviewIntroduction
Global prevalence and burden of COPD
Chronic Obstructive Pulmonary Disease (COPD) is a
progressive condition causing both pulmonary and sys-
temic consequences [1,2]. The estimated global preva-
lence in adults aged 40 years and over is 9-10% [3].
Prevalence is projected to increase as a result of past
high rates of tobacco use, and an ageing population
[4,5]. In addition to significant healthcare costs, COPD
causes a significant reduction in health-related quality of
life [6,7].* Correspondence: Jamie.Bryant@newcastle.edu.au
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reproduction in any medium, provided the orOptimal clinical management of COPD
Clinical practice guidelines recommend a multi-component
approach for management of COPD [8]. This includes both
oral and inhaled medications (e.g. bronchodilator therapy,
corticosteroid therapy and combination therapy) and non-
pharmacological interventions (e.g. pulmonary rehabilita-
tion, lifestyle advice and self-management techniques) to
slow disease progression, reduce exacerbations, and im-
prove quality of life. Correspondingly, medication ad-
herence is associated with reduced healthcare utilisation
[9], significantly better survival [10,11], and overall bet-
ter health outcomes [10,12,13]. However evidence sug-
gests that adherence to medication is often sub-optimal.Medication adherence among patients with COPD
Non-adherence to medication in COPD is high, with ad-
herence to inhaled and oral medications between 41.3%
and 57% [14,15]. Contributing factors include medicationLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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acteristics [15,16], and whether measurements to record
adherence is direct (i.e. observations and blood serum
measurements) or indirect (i.e. patient self-report, medica-
tion refill data and electronic records) [13]. Underuse of
medications is most common [17], with up to 49.4% not
taking nebulised treatments as prescribed [18-20]. Further,
31% employ ineffective inhaler dosing techniques [21] and
more than 50% over-utilise medications during periods of
respiratory distress [21].
Factors predicting medication adherence
Two distinct patterns of behaviour are associated with
medication non-adherence; intentional and unintentional
[22-24]. Intentional non-adherence is the deliberate dis-
continuation or reduction in use of therapy during periods
of symptom remission [25], often resulting from an erro-
neous understanding of the disease course and the goals
of treatment [26]. Unintentional non-adherence occurs
when patients do not adhere to treatment advice due to
reasons out of their control [24], often relating to
cognitive impairments, language barriers and physical
disability. In the case of COPD, impaired vision or mus-
culoskeletal problems affecting patient ability to use in-
haled medications can be attributable [27]. The most
commonly identified reason for unintentional non-
adherence is complex medication regimes [28] and
poly-pharmacy [29]. Multiple devices, poor awareness
and understanding of the nature of COPD [30,31] con-
fusion about prescribed medication regimes [25], and
high rates of depression [14] have also been shown to
negatively influence adherence.
Strategies to improve medication adherence
Several reviews have examined the effectiveness of strat-
egies including self-management, self-monitoring, and
education in increasing medication adherence for a
range of chronic conditions [32-35]. Few have found
strategies which predictably produce large increases in
adherence [35,36], however multi-dimensional interven-
tions have been shown to produce the largest effects
[37,38]. A recent review found more complex interven-
tions that involved various combinations of information,
reminders, self-monitoring, reinforcement, counselling,
crisis intervention and supportive care to be the most ef-
fective, however also noted that many studies were not
sufficiently powered to detect potentially clinically im-
portant effects [39]. A review by Rand and colleagues
concluded very few published studies focus on adher-
ence to treatment for COPD [40]. Given the high burden
of COPD, strong evidence of poor adherence, and some
differences in disease progression compared to other
chronic conditions, there is a critical need to determine
effective strategies to improve medication adherence.This review aims to examine:
1. The methodological quality of publications
examining the effectiveness of strategies to increase
medication adherence for management of COPD;




A number of terms have been used in the medical litera-
ture to describe health behaviour related to taking
treatment. Adherence and compliance are often used
interchangeably however these have different meanings
which must be recognised. Medication adherence refers
to the extent to which a patient’s behaviour in respect to
their medication matches the recommendations of the
prescriber [22,24,41]. The now largely obsolete term
medication compliance refers to the extent to which a
patient’s behaviour matches the prescriber’s advice [24].
Compliance is associated with negative connotations as
it infers an authoritarian relationship where the pre-
scribers’ role is to issue treatment and the patients’ role
is to follow orders [22,24]. Therefore the term adher-
ence has been used throughout this review.
Literature search
The electronic databases Medline and the Cochrane Li-
brary were searched using the following MeSH terms:
[Chronic Obstructive Pulmonary Disease OR Emphy-
sema OR Pulmonary emphysema OR Chronic Bronchitis
OR Obstructive Lung Diseases] AND [Medication ad-
herence OR Patient Compliance; Compliance]; and the
following keywords: [COPD] AND [patient adherence
OR adherence]. Searches were not limited by publication
year and restricted to English language human studies.
The reference lists of all included intervention studies
and identified reviews were also manually searched to
identify any other relevant studies.
Inclusion and exclusion criteria
Eligible studies were peer-reviewed intervention studies
that examined medication adherence as a primary or
secondary outcome measure in patients with a con-
firmed diagnosis of COPD. Studies that examined the
timing, dosage, and frequency of medication were in-
cluded. Papers related to adherence to oxygen therapy,
exercise, pulmonary rehabilitation, inhaler device profi-
ciency or self-management programs (without specific
mention of medication adherence) were excluded. Let-
ters, editorials, protocol papers, and case studies were
also excluded. Papers examining medication adherence
for other pulmonary diseases such as asthma were ex-
cluded, however studies which examined COPD together
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tients with COPD could be extracted separately to other
pulmonary diseases. This criterion was applied given
that COPD is a progressive disease, and that treatments
for COPD differ markedly compared to other respiratory
diseases [40].Data coding
Retrieved abstracts were initially assessed against the eligi-
bility criteria by one author (JM) and rejected if the study
did not meet inclusion criteria based on the title and
abstract. The remaining studies were assessed against the
inclusion criteria by two authors (JB and JM) and studies
which met all criteria were retained. Of these, studies were
assessed according to Effective Practice and Organisa-
tion of Care (EPOC) methodological criteria [42] and
included if they fulfilled the design criteria. These in-
cluded randomised controlled trials (RCT), controlled
clinical trials (CCT), controlled before and after studies
(CBA) and interrupted time series studies (ITS) [42].Included in review
n=7
Studies reported in 8 papers










Figure 1 Flow chart of search strategy and study selection and assignEach study was assessed independently by two reviewers
(JB and JM). Discrepancies were resolved through dis-
cussion between the reviewers. To assess intervention
effectiveness, study data was extracted and included:
aim of study; treatment type; study setting; sample char-
acteristics (sample size, gender, age, diagnosis, smoking
status); inclusion and exclusion criteria; intervention
design; outcome measures; follow-up periods and study
findings.Results
Search results
The initial search yielded 1,181 results with an additional
five studies identified through manual searches of refer-
ence lists. After removing 120 duplicates, 1,066 unique
papers were retained and assessed against eligibility cri-
teria. Of these, seven separate studies reported in eight
papers met criteria for inclusion in the review. A flow
chart of the literature search and paper identification is
provided in Figure 1.Excluded
n=950
Studies identified though additional 
searches and reference lists
n=5
Excluded n=108
- Descriptive studies (n=45)
- Reviews (n=23)
- Letter/editorial/commentaries (n=17)
- Trial protocols (n=8)
- COPD outcome not reported separately (n=8)
- Not intervention (n=2)
- Measurement studies (n=2)
- Abstract (n=1)
- Provider adherence (not patient related) (n=1)
- Not COPD (n=1)
ment.
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The characteristics of the studies are reported in Additional
file 1: Table S1. Three studies were conducted in the United
States [43-46] with the remainder in Norway [47], Spain
[48], Jordan [49] and the United Kingdom [50]. Adherence
to various medications were examined including (i) Theo-
phylline [43]; (ii) Prednisolone and β2 agonists [47]; (iii)
Short and long-acting β2 agonists, anticholinergic,
methylxanthines, inhaled and oral corticosteroids [48];
(iv) Short and long-acting β2 agonists, long acting anti-
cholinergic inhaled steroids, oral steroids, antibiotics
[49]; (v) Short and long-acting β2 agonist, long acting
anticholinergic, inhaled steroids, oral steroids [50]; and
(vi) Ipratropium bromide [44,45]. Medication adherence
was the primary outcome in five studies (reported in six
publications) [43-47,50], and a secondary outcome in
two [48,49]. Outcomes were measured directly (blood
serum ratios [43], observation of inhaler technique [48])
and indirectly (prescription refills [43], Medication
Adherence Scale [48], Inhaler Adherence Scale [48],
Moriksy Scale [46,49,50], inhaler device data [44,45],
patient self-report [44], pharmacy data [47], canister
weighing [44] and tablet counts [46]). Five studies
assessed adherence using two or more measures
[43-48]. Brief counselling [43], monitoring and feedback
about medication use [44,45], and multi-component
interventions were examined [44-50]; delivered by phar-
macists [43,46,49,50], general practitioners [47], and a
health educator [44,45]. Timing of outcome measures
was relatively homogenous, with the majority involving
a 6 and/or 12 month follow-up.Methodological quality
The methodological quality of included studies is
reported in Additional file 2: Table S2. Low risk of bias
was rated across all nine criteria in one study [48], and
across seven and eight criteria in two studies [47,49].
The remaining studies had differing methodological
limitations. There were four RCTs [46,48-50]. The re-
mainder were CCTs as the method used for random-
isation was inadequately detailed [43-45,47], such as
concealment of allocation to groups [43-45,47], and
limited clarity in whether baseline outcome measures
were similar prior to the intervention [43-46]. Two
studies were judged to have a high risk of bias as
baseline demographic characteristics between groups
were not reported [43-45]. One study was judged to
have a high risk of bias for selective outcome re-
porting, as only a statement that there was no differ-
ence in medication adherence for patients with COPD
was contained within the publication [46] and specific
data and measures of statistical significance were not
reported.Interventions that improved medication adherence
Additional file 1: Table S1 describes the characteristics
of the included studies. Interventions were behavioural
interventions including brief counselling and monitoring
and feedback, and multi-component interventions com-
bining behavioural and educational approaches. Five
studies (reported in six publications) found positive re-
sults [43-45,48-50].
Brief counselling
De Tullio and colleagues [43] examined the effectiveness
of brief counselling compared to usual care on adher-
ence to theophylline in a veteran population. Interven-
tion participants received 3–5 minutes of counselling on
theophylline and the importance of taking medication as
recommended, delivered by a pharmacist following a rou-
tine physician visit. Counselling significantly improved ad-
herence measured by drug serum levels at 4.5 months
post-intervention, and prescription refills at 6 months
post-intervention (p = .4).
Monitoring and feedback
Nides and colleagues [44] examined the effectiveness of
a Nebuliser Chronolog feedback system, as part of a lar-
ger 12 week smoking cessation Lung Study [51]. The
Nebuliser Chronolog is a microprocessor device with the
ability to record the date and time of each inhaler actu-
ation. The intervention group received the Nebuliser
Chronolog, were informed of the device capabilities and
provided with printed feedback of their recordings after
weeks one and seven. Participants also had brief sessions
with a health educator who reviewed inhaler usage and
provided individual feedback at each four month follow-
up. The control group were given the Nebuliser Chronolog
and were only informed the device recorded the amount of
inhaled drug use. At the four month follow-up the inter-
vention group showed significantly better adherence to the
prescribed three sets of medication each day (p = .003), had
greater proportion of adherent days (p < .0001) and had
greater proportion of inhalations taken as prescribed
(p < .0001) than the control group. Simmons and col-
leagues [45] reported the results from this study for the
four month follow-up through to the 24 month follow-up.
A significantly higher level of adherence was shown for the
intervention group at each individual follow-up period
(p < .05). Both groups showed a statistically significant dif-
ference between these intervals for every follow-up period.
Multi-component interventions
Three studies examining multi-component interventions
were effective. One of the most complex interventions ex-
amined an integrated self-management and co-ordination
of care intervention in patients discharged from hospital
after exacerbation of COPD [48]. Patients received (i) an
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their primary care team; (ii) a two-hour individual educa-
tion session about self-management with written educa-
tional information; (iii) a visit by a nurse and primary care
team within 72 hours of discharge; (iv) weekly phone calls
from a specialised case manager nurse in the first month
post-discharge, then phone calls at 3 and 9 months, as
well as the option to phone the nurse if symptoms of
COPD worsened. Adherence to inhaled treatments signifi-
cantly increased at 12 months (intervention, 71%; control,
37%; p = .009), as well as correct inhaler use (p < .001).
There were no differences between groups in adherence
to oral treatments, but rates were already high with 85%
adherence in the control group and 90% adherence in the
intervention group at 12 months. Improvements in dis-
ease knowledge and nutritional status, and reductions in
hospital admissions were also found.
Structured face-to-face motivational interviewing from
a pharmacist at an outpatient clinic, the provision of a
medication table, and education about symptom control,
technique for expectoration and the importance of sim-
ple exercises had a positive impact on adherence to
short and long acting β agonists, inhaled and oral ste-
roids and antibiotics at 6 months follow-up (p < .05)
[49]. Positive effects were also found for a more intensive
individually tailored pharmacist-delivered intervention
[50] involving a one-hour face-to-face education session
on COPD, medications and breathing techniques; educa-
tional booklets on techniques for improving health status;
a customised action plan; and telephone follow-up. Parti-
cipants who smoked received motivational interviewing
and were provided with a referral to hospital smoking
cessation programs. There were significant improvements
in medication adherence at 6 months (intervention, 81%;
control, 63%; p = .019) and 12 months follow-up (inter-
vention, 78%; control, 60%; p = .019).
Interventions that did not improve medication adherence
Two studies found no significant effect on adherence
[46,47]. Both used multi-component approaches.
Gallefoss and colleagues [47] examined the effectiveness
of face-to-face education program and self-management
plan compared to usual general practitioner care on ad-
herence to Prednisolone and β2 agonists. Participants re-
ceived an educational patient brochure, two 2-hour group
sessions focusing on pathophysiology of disease, medica-
tions, symptom awareness and treatment plans, and either
one or two 40-minute individual sessions delivered by a
trained nurse and physiotherapist. An individual treat-
ment self-management plan was provided at the final
face-to-face session, and the patients’ personal under-
standing of the plan was discussed and tested. No signifi-
cant differences in steroid inhaler adherence or use of oral
steroids were found at 12 months follow-up. Overalladherence at 12 months was 50% in the intervention
group, and 58% in the control group.
Solomon and colleagues [46] examined the effective-
ness of a pharmaceutical care intervention in an ambula-
tory setting. The intervention group received face-to-
face and telephone pharmaceutical care from a clinical
pharmacist and pharmacy residents which included: (i)
management of drug therapy; (ii) pharmacist and phys-
ician collaboration to implement patient-specific stepped
care; (iii) education about COPD; (iv) counselling to ad-
dress patient concerns; (v) patient assessment and care
through clinic visits and telephone follow-up. The au-
thors state that there were no significant differences in
medication adherence between intervention and control
groups at 6 months follow-up, however specific data
were not reported.
Discussion
Currently available pharmacotherapy for COPD can sig-
nificantly reduce the frequency and length of exacerba-
tions, reduce hospital admissions and therefore the cost
of care, and slow disease progression [9,10]. However,
medications are optimally effective when used as pre-
scribed. This systematic review examined the effective-
ness of interventions designed to improve medication
adherence for individuals with COPD. Of the seven
intervention studies identified, five found improvements
in adherence at either short or long term follow-up pe-
riods [43,44,48-50].
Methodological quality
Overall, methodological quality of studies included in the
review was variable. Recurring limitations included inad-
equacies in describing randomisation methods, assessing
similarities of baseline characteristics between groups,
unblended assessment of primary outcome measures and
failure to report study power. This compromises the
strength of evidence.
Various measures of medication adherence were used
which made it difficult to compare rates and effect of in-
terventions across studies, precluding the aggregation of
findings in meta-analysis. The lack of a gold-standard
measure of medication adherence and the need for con-
sensus about a uniform measure has been well docu-
mented [52,53], but is critical to resolve to move the
evidence base in this area forward.
Effectiveness of strategies to improve medication
adherence
The majority of studies included in this review utilised
multi-component strategies, however specific interven-
tion components of success could not be determined. In
addition, it would also be useful for future studies to ex-
plore issues of the relative costs and benefits of more
Bryant et al. Respiratory Research 2013, 14:109 Page 6 of 8
http://respiratory-research.com/content/14/1/109intensive versus less intensive approaches given the in-
creasing pressure on limited health care resources.
Studies that showed statistically significant intervention
effects did not necessarily result in improved adherence.
In one study for example, only 71% of the intervention
group were adherent at 12 months follow-up and only
86% correctly used inhaler therapies [48]. Similarly in an-
other study, despite structured face-to-face motivational
interviewing increasing adherence compared to a control
group, nearly one third of participants were still non-
adherent at 6 months follow-up [49]. Achieving optimal
adherence and determining which interventions achieve
highest level of adherence is an important and ongoing
issue. Our findings suggest further research is needed to
identify effective strategies.
Implications and directions for future research
The reasons for non-adherence among patients with
COPD are multi-factorial and complex. Future research
should further explore the multi-component interventions
found effective in the two most rigorous studies included
in the review [48,49]. Also, strategies demonstrating bene-
fits for other chronic diseases, and directly address key
problems that affect adherence for COPD, such as com-
plex medication regimes, should also be further explored.
Shared decision making
None of the studies described the use of shared decision
making in their interventions. A person-centred ap-
proach to care where the agendas’ of the patient and
health care provider are addressed and agreed upon may
effectively improve adherence in COPD [54]. A recent
study examined the effect of shared decision making
compared to clinician decision making among patients
with asthma, using adherence to controller therapy as
the outcome [55]. In the shared decision making group,
participants negotiated their treatment, had the oppor-
tunity to summarise treatment goals, and were provided
with information on treatment and treatment options.
Statistically significant improvements in adherence and
clinical outcomes were demonstrated [55].
Interventions that target the physician
Optimal medication use requires collaborative interven-
tions that address patient barriers but also provider
prescribing behaviour. All studies identified focused on
patient education and counselling rather than system or
provider-level interventions. Enhancing provider skills in
patient education, communication, and adherence coun-
selling has been explored in diseases such as asthma and
resulted in improved satisfaction and health outcomes
for patients [56]. Simplifying medication regime, wher-
ever possible, should also be explored. Changes in dos-
ing regimen to limit the number of doses required perday improved adherence for hypertension and cholesterol
treatment [35]. No studies specified that they attempted
to simplify the medication regime.
Involving caregivers
A caregiver is generally defined as an unpaid individual
that provides physical or emotional support [57]. A re-
cent study demonstrated positive associations between
having a caregiver (spousal or non-spousal) and adher-
ence in COPD patients, with better adherence to antihy-
pertensive and long acting β agonist medications, and
less likely to smoke than those without [58]. No studies
included in the review examined the influence of care-
givers. Future intervention studies could explore this, in-
cluding active encouragement to be part of the patients
care during clinical appointments, and targeted educa-
tion about the importance of medication adherence.
Limitations of the review
Our findings should be considered in light of several limi-
tations. Firstly, the review only identified publications in
peer-reviewed journals. However, it is unlikely that rigor-
ous studies finding a positive intervention effect exist in
the unpublished literature. Secondly, meta-analysis was not
possible given the wide variety of measures used to assess
medication adherence. Finally, we included studies that
evaluated interventions to improve medication adherence.
We acknowledge the importance of non-pharmacological
interventions in COPD such as physical activity, nutrition
and other lifestyle recommendations, and that interven-
tions that improve adherence to these treatment recom-
mendations also require evaluation.
Conclusions
Improving medication adherence among individuals with
COPD is critical to optimising patient outcomes. There
is a clear need for rigorous research to determine effect-
ive interventions for improving medication adherence
for individuals with COPD. Future research should con-
sider interventions that have been successful in other
chronic diseases such those involving partnerships be-
tween patients and clinicians.
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